Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure i...
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
- Associated Therapies
- -
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02172794
Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 623
- Registration Number
- NCT02172287
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT02055352
- Locations
- 🇵🇦
Novartis Investigative Site, Panama City, Panamá, Panama
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 229
- Registration Number
- NCT01969721
- Locations
- 🇨🇿
1237.11.42004 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇩🇪1237.11.49003 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany
🇩🇪1237.11.49005 Boehringer Ingelheim Investigational Site, Hamburg, Germany
Effects of Particle Size in Small Airways Dysfunction
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 17
- Registration Number
- NCT01892787
- Locations
- 🇬🇧
Brian Lipworth, Dundee, United Kingdom
Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 49
- Registration Number
- NCT01853787
- Locations
- 🇮🇹
: Pneumologia Riabilitativa-Fondazione Maugeri-Istituto Scientifico di Milano- IRCCS, Milano, Italy
🇮🇹Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Scienze Mediche, Università di Ferrara, Ferrara, Italy
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 629
- Registration Number
- NCT01636076
- Locations
- 🇹🇭
Novartis Investigative Site, Songkla, Thailand
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 581
- Registration Number
- NCT01555138
- Locations
- 🇬🇧
Novartis Investigative Site, Surrey, United Kingdom
Effects of Salmeterol on Autonomic Nervous System
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT01536587
- Locations
- 🇩🇪
GSK Investigational Site, Goettingen, Niedersachsen, Germany
Management of Asthma in School-age Children on Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Professor Warren Lenney
- Target Recruit Count
- 229
- Registration Number
- NCT01526161
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.